KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks
$5.03
+0.150 (+3.07%)
At Close: Apr 26, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $4.61 $7.24 Friday, 26th Apr 2024 AFMD stock ended at $5.03. This is 3.07% more than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 6.35% from a day low at $4.88 to a day high of $5.19.
90 days $4.25 $7.24
52 weeks $2.24 $11.10

Historical Affimed N.V. prices

Date Open High Low Close Volume
Feb 16, 2022 $45.10 $45.80 $44.05 $45.00 61 590
Feb 15, 2022 $43.90 $46.65 $43.90 $45.50 110 190
Feb 14, 2022 $42.30 $43.60 $41.80 $42.50 79 720
Feb 11, 2022 $43.30 $44.30 $41.90 $42.10 101 540
Feb 10, 2022 $42.60 $45.50 $42.30 $43.40 91 890
Feb 09, 2022 $41.75 $44.00 $41.75 $43.90 100 330
Feb 08, 2022 $41.10 $42.30 $40.40 $42.20 95 930
Feb 07, 2022 $39.00 $41.30 $38.90 $41.20 99 360
Feb 04, 2022 $38.90 $39.60 $37.35 $38.90 129 280
Feb 03, 2022 $39.20 $39.20 $37.80 $38.40 76 880
Feb 02, 2022 $42.40 $42.70 $39.40 $39.60 68 620
Feb 01, 2022 $41.10 $43.10 $40.55 $42.10 141 920
Jan 31, 2022 $38.60 $41.25 $38.60 $40.80 160 450
Jan 28, 2022 $36.90 $38.60 $35.90 $38.50 110 450
Jan 27, 2022 $40.40 $40.55 $36.70 $36.90 135 730
Jan 26, 2022 $40.10 $42.20 $39.30 $39.80 196 120
Jan 25, 2022 $40.30 $40.80 $38.60 $39.60 82 640
Jan 24, 2022 $40.00 $41.20 $37.50 $40.90 192 280
Jan 21, 2022 $40.80 $42.00 $40.20 $40.20 106 290
Jan 20, 2022 $43.20 $44.40 $41.30 $41.40 60 540
Jan 19, 2022 $42.50 $44.18 $42.50 $42.60 95 120
Jan 18, 2022 $43.90 $43.90 $42.10 $42.20 93 890
Jan 14, 2022 $43.60 $44.50 $42.00 $44.40 99 020
Jan 13, 2022 $45.20 $46.00 $43.35 $44.10 168 340
Jan 12, 2022 $47.20 $48.40 $44.70 $44.70 108 960
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Golden Star

Ticker Date Change Price
DHT Apr 24 2.04% $11.28
MLI Apr 19 9.66% $52.28
LPLA Apr 19 1.42% $262.59
DOOR Apr 18 0.167% $131.39
LNG Apr 17 1.49% $156.81
FCN Apr 16 1.80% $207.62
ELV Apr 16 5.97% $506.97
AKR Apr 05 4.78% $16.53
ITCI Apr 05 7.04% $68.44
VSTS Apr 04 0.425% $18.82
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT